Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06131398 · ClinicalTrials.gov registry record · Phase 1

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Amgen.

Active
Registry status
Phase 1
Development phase
77
Enrollment target
20
Study locations

NCT06131398 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Amgen. The registered enrollment target is 77 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06131398, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Amgen.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
77 participants
Enrollment target
20
Study locations

Study Summary

The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Pembrolizumab
  • DRUG AMG 355

Study Locations (20)

Other

  • Institut Bergonie - Bordeaux
  • Gustave Roussy - Villejuif
  • Radboud Universitair Medisch Centrum - Nijmegen
  • Erasmus Medisch Centrum - Rotterdam
  • Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy - Warsaw
  • Seoul National University Hospital - Seoul
  • Asan Medical Center - Seoul

Catalonia

  • Hospital Universitari Vall d Hebron - Barcelona
  • Hospital Clinic i Provincial de Barcelona - Barcelona

California

  • City of Hope National Medical Center - Duarte

Kansas

  • Alliance for Multispecialty Research - Kansas City - Merriam

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Washington University - St Louis

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Texas

  • South Texas Accelerated Research Therapeutics - San Antonio

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2024-03-07
Est. Completion 2026-08-03
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06131398

The ClinicalTrials.gov registry entry for NCT06131398 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (61% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT06131398 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Catalonia, California.

Frequently Asked Questions

What is clinical trial NCT06131398 about?

NCT06131398 is a clinical study titled "A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors". The primary objectives of this study are to: * Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors * Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in co...

What is the current status of trial NCT06131398?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2024-03-07. Estimated completion is 2026-08-03.

What conditions does trial NCT06131398 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06131398?

The interventions under investigation include: Pembrolizumab (DRUG), AMG 355 (DRUG).

Who is sponsoring clinical trial NCT06131398?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06131398 being conducted?

This trial has 20 study locations across California, Kansas, Massachusetts, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.